Varenicline Tablet, Film Coated
Product Images NDC 70518-4647

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 70518-4647). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Varenicline Tablet, 0.5 mg, film-coated oral tablet. The package contains 1 tablet. Labeled for prescription use only by RemedyRepack Inc., Indiana, PA. Includes storage instructions and manufacturer information for Camber Pharma, Inc., Piscataway, NJ. NDC number 70518-4647-01 is indicated.*

FDA Label Image

Vareniclinecamberlogo (Vareniclinecamberlogo)

FDA Label Image

Vareniclinefigure1 (Vareniclinefigure1)

A bar chart comparing the percentages of an unspecified measure across four treatment groups: Varenicline 0.5 mg BID, Varenicline 1.0 mg BID, Placebo, and Bupropion SR 150 mg BID. Data is separated into four studies (Study 2, Study 3, Study 4, and Study 5) with each study showing results for different treatment groups, indicating variability in the measure across the studies and treatments. Error bars are included for variability.*

FDA Label Image

Vareniclinefigure2 (Vareniclinefigure2)

A bar chart comparing the percentage outcomes of various treatments in five different studies. Treatments include Varenicline 0.5 mg BID, Varenicline 1.0 mg BID, Varenicline Flexible dosing, Bupropion SR 150 mg BID, and Placebo. Each study groups these treatments and visually shows their relative effectiveness as indicated by the bar heights with error bars.*

FDA Label Image

Vareniclinefigure3 (Vareniclinefigure3)

A line graph comparing the percentage of continuous abstinent individuals over nontreatment follow-up weeks between Varenicline 1.0 mg BID and placebo groups. The x-axis shows weeks of follow-up with two numbers per point, and the y-axis shows the percentage continuous abstinent from 0 to 100.*

FDA Label Image

Vareniclinestructure (Vareniclinestructure)

Chemical structure of Varenicline tartrate, the active ingredient in Varenicline tablets, film coated (0.5 mg) by RemedyRepack Inc. The image shows the molecular formula with the bicyclic pyridine and pyrrolidine rings and the tartrate salt representation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.